Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Iron
Drug ID BADD_D01197
Description A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia.
Indications and Usage Used in preventing and treating iron-deficiency anemia.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB01592
KEGG ID Not Available
MeSH ID D007501
PubChem ID 23925
TTD Drug ID D0Y3TM
NDC Product Code 0220-2054; 62106-5042; 68428-383; 64117-791; 0220-2051; 0164-1152
UNII E1UOL152H7
Synonyms Iron | Iron-56 | Iron 56
Chemical Information
Molecular Formula Fe
CAS Registry Number 7439-89-6
SMILES [Fe]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ventricular extrasystoles02.03.04.007---
Ventricular fibrillation02.03.04.008--
Vertigo04.04.01.003; 17.02.12.0020.000453%
Viral infection11.05.04.001---
Visual impairment06.02.10.0130.000680%-
Vitamin B12 deficiency14.12.02.0040.000453%-
Vomiting07.01.07.0030.003400%
Vulvovaginal dryness21.08.02.0030.000997%
Wheezing22.03.01.009--
Mobility decreased08.01.03.030; 15.03.05.023; 17.02.05.0180.000680%-
Infusion site erythema08.02.05.008; 12.07.05.009; 23.03.06.016---
Poor venous access24.03.02.017---
Seasonal allergy06.04.01.013; 10.01.04.001; 22.04.04.008---
Peripheral swelling02.05.04.015; 08.01.03.0530.000453%-
Emotional distress19.04.02.008---
General physical health deterioration08.01.03.0180.001360%-
Blood phosphorus decreased13.11.01.015---
Muscle tightness15.05.03.007---
Lupus-like syndrome10.04.03.003; 15.06.02.004; 23.03.02.004---
Skin tightness23.03.03.018---
Musculoskeletal chest pain15.03.04.012; 22.09.01.001--
Deep vein thrombosis24.01.02.0030.000453%-
Hyperphosphaturia14.04.03.006; 20.02.01.025---
Injection site discolouration08.02.03.038; 12.07.03.038; 23.03.03.046---
Large intestine polyp07.20.01.010; 16.05.02.006---
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Conjunctival hyperaemia06.04.01.0040.000453%-
Ear discomfort04.03.01.005---
Ear pruritus04.03.01.011---
Ocular discomfort06.08.03.008---
The 11th Page    First    Pre   11 12 13 14    Next   Last    Total 14 Pages